BTAI - BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.

52W High

$13.36

52W Low

$1.17

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.21

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.76

EV/Revenue (<3 favorable)

168.98

P/S (TTM) (<3 favorable)

63.56

P/B (<3 favorable)

3.97

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

3.80%

Institutions (25–75% balanced)

6.23%

Shares Outstanding

14,556,700

Float

14,009,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

868,000

Gross Profit (TTM)

-1,255,000

EPS (TTM)

-11.90

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-132.10%

ROE (TTM) (>15% strong)

-17.67%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.89

Momentum

Bearish momentum

Value

-0.1428

-0.0704

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025